Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Suki

Suki raises $90M to push its clinical AI beyond documentation and into agents

Healthier Capital, Crosslink Capital and Hercules Capital joined the Series E. Suki says its revenue doubled last year and sales to companies that embed its AI have grown more than tenfold in two years.

Charted Staff2 min read
From a company announcement published Oct. 13, 2026
A doctor talks with a couple across a consultation table.
A doctor talks with a couple across a consultation table. File photo.Rhoda Baer, National Cancer Institute (public domain)
Amount
$90M
Type
Series E+
Company
Suki
Sector
Health AI
Announced
Oct. 13, 2026

Suki made its name turning doctor-patient conversations into clinical notes. With a $90 million Series E announced Oct. 13, the Redwood City, Calif., company is telling investors and customers that notes were only the start.

New investors Healthier Capital, Crosslink Capital and Hercules Capital joined the round, and every existing institutional investor took part, including Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures, the company said. The announcement named no lead investor and did not disclose a valuation.

Why it matters: Suki sells its AI two ways: directly to clinicians, and as a component that other health software companies build into their own products. The company said revenue from that partner business rose more than tenfold over the past two years, while total revenue doubled in 2025.

From notes to agents

Suki said its software now reaches past note-taking into clinical reasoning, billing and revenue-cycle tasks, and other operational work. Its products include Suki for Clinicians, its own app, and Suki for Partners, a set of software development kits and APIs. The week before the announcement, it announced Ask, which puts clinical reference content from UpToDate Expert AI, a Wolters Kluwer product, inside clinicians' workflows.

"Clinical documentation was never the destination. It was the entry point," Punit Soni, Suki's founder and chief executive, said in the announcement.

The company said over 450 healthcare organizations use its clinician app and over 30 technology partners embed its AI in their own platforms. It said the number of patient encounters its software supports rose more than 190% from a year earlier in 2026, and that revenue is on pace for similar growth this year. Suki did not disclose revenue figures.

Suki framed the round around fragmentation. As health systems adopt AI, it said, they are stacking up single-purpose products that often do not connect to the work around them. Its response is what it calls an open ecosystem, in which partners either embed Suki's technology or contribute their own data and intelligence.

Aman Mahajan, a partner at Healthier Capital, is joining Suki's board. His past posts include UPMC and UCLA Health, according to the release.

"The real opportunity for AI in healthcare isn't to automate individual tasks. It's to rethink how work gets done across the health system," Mahajan said.

What comes next

Suki said the money will fund faster growth and investment in its partner ecosystem, its AI, its integrations and its commercial team. The company said it plans to share more about the next version of its technology but gave no timeline.

Its boilerplate also lists First Round and March Capital among its backers. The release did not say how much Suki has raised in total.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.